Besides showing skepticism on the budget, senators grilled the NIH director about a leadership vacuum, two viral outbreaks, and the pace of funding.

A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor ...

On this week’s episode of “The Readout LOUD,” the hosts discuss STAT's Breakthrough Summit West, where powerful leaders from ...

Peter Haytaian, a former top executive at health insurance company Elevance Health, will have to sit for a deposition in the ...

Watch as NIH Director Jay Bhattacharya is questioned by the Senate Appropriations Committee this morning on President Trump’s ...

Jeffery Taubenberger, the acting head of the NIAID, the NIH’s infectious disease institute, is reported to have stepped down.

Eli Lilly reported that in a late-stage trial, its next-generation obesity drug led to weight loss approaching the ...

Whoop is yet to resolve a dispute with the FDA over a blood pressure feature, a top executive said at STAT's Breakthrough ...

A next-gen Eli Lilly obesity drug led to bariatric-surgery levels of weight loss in a study, but also saw patients dropping ...

In this edition of AI Prognosis, Brittany Trang explains in detail why 'AI co-scientist' tools may not be as helpful for ...

It almost feels like the Trump administration is intentionally breaking the FDA, writes Lab Dish columnist Paul Knoepfler.

The federal government is sending nearly $8 billion in supplemental Medicaid funds to hospitals in Florida for care they ...